OnKure Therapeutics Management
Management criteria checks 2/4
OnKure Therapeutics' CEO is Nick Saccomano, appointed in Sep 2023, has a tenure of 1.17 years. total yearly compensation is $346.39K, comprised of 19.5% salary and 80.5% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth $226.22K. The average tenure of the management team and the board of directors is 1.8 years and 3.7 years respectively.
Key information
Nick Saccomano
Chief executive officer
US$346.4k
Total compensation
| CEO salary percentage | 19.5% |
| CEO tenure | 1.2yrs |
| CEO ownership | 0.1% |
| Management average tenure | 1.8yrs |
| Board average tenure | 3.7yrs |
Recent management updates
No updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$45m |
| Jun 30 2024 | n/a | n/a | -US$42m |
| Mar 31 2024 | n/a | n/a | -US$36m |
| Dec 31 2023 | US$346k | US$68k | -US$35m |
Compensation vs Market: Nick's total compensation ($USD346.39K) is below average for companies of similar size in the US market ($USD1.46M).
Compensation vs Earnings: Insufficient data to compare Nick's compensation with company performance.
CEO
Nick Saccomano (65 yo)
1.2yrs
Tenure
US$346,392
Compensation
Dr. Nicholas A. Saccomano, Ph D., also known as Nick, serves as President & Chief Executive Officer at OnKure Therapeutics, Inc. from September 2023 and is its Director since January 2022. Dr. Saccomano se...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.2yrs | US$346.39k | 0.11% $ 226.2k | |
| Chief Financial Officer | 2.8yrs | US$791.95k | 0.027% $ 54.5k | |
| Chief Scientific Officer | less than a year | no data | no data | |
| General Counsel & Secretary | less than a year | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Senior Vice President of Computational Drug Discovery | 3.3yrs | no data | 0.88% $ 1.8m | |
| Chief Development Officer | 3.3yrs | no data | no data | |
| Senior Vice President of DMPK & Clinical Pharmacology | 2.4yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data | |
| Senior Vice President of Discovery Chemistry | no data | no data | no data |
1.8yrs
Average Tenure
53.5yo
Average Age
Experienced Management: OKUR's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.8yrs | US$346.39k | 0.11% $ 226.2k | |
| Member of Scientific Advisory Board | 3.4yrs | no data | no data | |
| Director | less than a year | no data | 0.47% $ 944.5k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Director | 3.7yrs | US$124.79k | 0.038% $ 77.0k | |
| Independent Director | 3.7yrs | no data | 0.032% $ 63.8k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Chairman | 3.7yrs | no data | 0.032% $ 63.8k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | less than a year | no data | 0.032% $ 63.8k | |
| Member of Scientific Advisory Board | no data | no data | no data |
3.7yrs
Average Tenure
58.5yo
Average Age
Experienced Board: OKUR's board of directors are considered experienced (3.7 years average tenure).